Axsome Therapeutics Inc
NASDAQ:AXSM

Watchlist Manager
Axsome Therapeutics Inc Logo
Axsome Therapeutics Inc
NASDAQ:AXSM
Watchlist
Price: 86.95 USD -4.17% Market Closed
Market Cap: 4.2B USD
Have any thoughts about
Axsome Therapeutics Inc?
Write Note

Wall Street
Price Targets

AXSM Price Targets Summary
Axsome Therapeutics Inc

Wall Street analysts forecast AXSM stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AXSM is 134.07 USD with a low forecast of 106.05 USD and a high forecast of 189 USD.

Lowest
Price Target
106.05 USD
22% Upside
Average
Price Target
134.07 USD
54% Upside
Highest
Price Target
189 USD
117% Upside

AXSM Last Price Targets
Axsome Therapeutics Inc

The latest public price target was made on Nov 12, 2024 by Yatin Suneja from Guggenheim , who expects AXSM stock to rise by 55% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Yatin Suneja
Guggenheim
135 USD
Upside 55%
1 month ago
Nov 12, 2024
Axsome Therapeutics (AXSM) PT Raised to $135 at Guggenheim
StreetInsider
Graig Suvannavejh
Mizuho Securities
106 USD
Upside 22%
3 months ago
Sep 11, 2024
Mizuho Reiterates Outperform Rating on Axsome Therapeutics (AXSM)
StreetInsider
Cerena Chen
Wells Fargo
140 USD
Upside 61%
3 months ago
Sep 3, 2024
Axsome Therapeutics initiated with an Overweight at Wells Fargo
TheFly
Raghuram Selvaraju
H.C. Wainwright
180 USD
Upside 107%
4 months ago
Aug 6, 2024
Axsome Therapeutics price target lowered to $180 from $190 at H.C. Wainwright
TheFly
Jason Gerberry
Bank of America Securities
106 USD
Upside 22%
4 months ago
Aug 6, 2024
BofA Securities Upgrades Axsome Therapeutics (AXSM) to Buy
StreetInsider
Leonid Timashev
RBC Capital
131 USD
Upside 51%
5 months ago
Jul 22, 2024
RBC Capital Reiterates Outperform Rating on Axsome Therapeutics (AXSM)
StreetInsider
Leonid Timashev
RBC Capital
130 USD
Upside 50%
6 months ago
Jun 5, 2024
Axsome Therapeutics (AXSM) PT Raised to $130 at RBC Capital
StreetInsider
David Amsellem
Piper Sandler
115 USD
Upside 32%
6 months ago
May 28, 2024
Piper Sandler Reiterates Overweight Rating on Axsome Therapeutics (AXSM)
StreetInsider
Vikram Purohit
Morgan Stanley
115 USD
Upside 32%
7 months ago
Apr 29, 2024
Morgan Stanley Upgrades Axsome Therapeutics (AXSM) to Overweight, 'attractive risk/reward heading into 2H24'
StreetInsider
Graig Suvannavejh
Mizuho Securities
109 USD
Upside 25%
8 months ago
Mar 28, 2024
Axsome Therapeutics (AXSM) PT Raised to $109 at Mizuho
StreetInsider
Joel Beatty
Robert W. Baird
108 USD
Upside 24%
9 months ago
Mar 18, 2024
Baird Starts Axsome Therapeutics (AXSM) at Outperform, 'we anticipate the sales trajectory will remain strong'
StreetInsider
Show More Price Targets
Show Less Price Targets
Yatin Suneja
Guggenheim
Price Target 135 USD
Upside/Downside 55%
View Source
Graig Suvannavejh
Mizuho Securities
Price Target 106 USD
Upside/Downside 22%
View Source
Cerena Chen
Wells Fargo
Price Target 140 USD
Upside/Downside 61%
View Source
Raghuram Selvaraju
H.C. Wainwright
Price Target 180 USD
Upside/Downside 107%
View Source
Jason Gerberry
Bank of America Securities
Price Target 106 USD
Upside/Downside 22%
View Source
Leonid Timashev
RBC Capital
Price Target 131 USD
Upside/Downside 51%
View Source
Leonid Timashev
RBC Capital
Price Target 130 USD
Upside/Downside 50%
View Source
David Amsellem
Piper Sandler
Price Target 115 USD
Upside/Downside 32%
View Source
Vikram Purohit
Morgan Stanley
Price Target 115 USD
Upside/Downside 32%
View Source
Graig Suvannavejh
Mizuho Securities
Price Target 109 USD
Upside/Downside 25%
View Source
Joel Beatty
Robert W. Baird
Price Target 108 USD
Upside/Downside 24%
View Source
Show More Price Targets
Show Less Price Targets
Axsome Therapeutics Inc Competitors:
Price Targets
300401
Zhejiang Garden Bio-chemical High-tech Co Ltd
17% Upside
INVA
Innoviva Inc
9% Upside
SECARE
Swedencare AB (publ)
26% Upside

Revenue
Forecast

Revenue Estimate
Axsome Therapeutics Inc

The compound annual growth rate of Axsome Therapeutics Inc's revenue for the next 4 years is 54%.

N/A
Past Growth
54%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Axsome Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Net Income
Forecast

Net Income Estimate
Axsome Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-26%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is AXSM's stock price target?
Price Target
134.07 USD

According to Wall Street analysts, the average 1-year price target for AXSM is 134.07 USD with a low forecast of 106.05 USD and a high forecast of 189 USD.

What is Axsome Therapeutics Inc's Revenue forecast?
Projected CAGR
54%

The compound annual growth rate of Axsome Therapeutics Inc's revenue for the next 4 years is 54%.

Back to Top